Stockscreener 앱 받기
29.86
1.77%
0.52
전일 마감가:
$29.34
열려 있는:
$29.53
하루 거래량:
381.71K
Relative Volume:
0.18
시가총액:
$567.89M
수익:
$90.12M
순이익/손실:
$-276.06M
주가수익비율:
-20.45
EPS:
-1.46
순현금흐름:
$-193.47M
1주 성능:
+10.47%
1개월 성능:
+30.34%
6개월 성능:
+3,650%
1년 성능:
+2,251%
1일 변동 폭
$28.61
$29.92
1주일 범위
$26.45
$29.92
52주 변동 폭
$0.432
$37.38
넥타테라퓨틱스 Stock (NKTR) Company Profile
명칭
Nektar Therapeutics
전화
(415) 482-5300
주소
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
NKTR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NKTR
Nektar Therapeutics
|
29.86 | 558.00M | 90.12M | -276.06M | -193.47M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.02 | 100.52B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.70 | 61.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
446.51 | 59.29B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
712.20 | 43.09B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
306.05 | 35.42B | 3.81B | -644.79M | -669.77M | -6.24 |
넥타테라퓨틱스 Stock (NKTR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-24 | 재확인 | BTIG Research | Buy |
| 2025-06-24 | 재확인 | H.C. Wainwright | Buy |
| 2025-04-11 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-03-14 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-01-08 | 개시 | B. Riley Securities | Buy |
| 2024-12-10 | 개시 | H.C. Wainwright | Buy |
| 2024-11-04 | 개시 | Piper Sandler | Overweight |
| 2024-09-30 | 재개 | BTIG Research | Buy |
| 2024-06-28 | 개시 | Rodman & Renshaw | Buy |
| 2023-11-20 | 재개 | JP Morgan | Underweight |
| 2023-11-09 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-05-10 | 업그레이드 | Jefferies | Underperform → Hold |
| 2023-02-24 | 다운그레이드 | Jefferies | Hold → Underperform |
| 2022-08-08 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-05-31 | 재개 | Jefferies | Hold |
| 2022-04-18 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-03-15 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2022-03-15 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-03-14 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2022-03-14 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-03-14 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-03-14 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2022-03-09 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-11-08 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-09-10 | 개시 | BofA Securities | Neutral |
| 2021-06-28 | 업그레이드 | Stifel | Hold → Buy |
| 2021-05-18 | 재개 | Goldman | Neutral |
| 2021-02-22 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2021-01-06 | 개시 | Stifel | Hold |
| 2020-09-14 | 개시 | JP Morgan | Neutral |
| 2020-06-10 | 다운그레이드 | CFRA | Hold → Sell |
| 2020-05-12 | 재확인 | H.C. Wainwright | Neutral |
| 2020-04-22 | 개시 | The Benchmark Company | Buy |
| 2020-03-30 | 업그레이드 | Goldman | Sell → Neutral |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-02-03 | 업그레이드 | Mizuho | Neutral → Buy |
| 2019-10-24 | 개시 | Oppenheimer | Perform |
| 2019-10-08 | 다운그레이드 | Goldman | Buy → Sell |
| 2019-08-09 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-08-09 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-08-09 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2019-03-15 | 개시 | SVB Leerink | Mkt Perform |
| 2018-12-13 | 개시 | Goldman | Buy |
| 2018-06-11 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2018-06-04 | 재확인 | H.C. Wainwright | Buy |
| 2018-04-20 | 개시 | Seaport Global Securities | Buy |
| 2018-04-13 | 재개 | Piper Jaffray | Overweight |
| 2018-04-06 | 재확인 | Mizuho | Buy |
| 2018-04-02 | 재개 | H.C. Wainwright | Buy |
모두보기
넥타테라퓨틱스 주식(NKTR)의 최신 뉴스
Automated trading signals detected on Nektar Therapeutics2025 Market Sentiment & Breakout Confirmation Trade Signals - Newser
Candlestick signals on Nektar Therapeutics stock todayTrade Volume Summary & Stock Market Timing Techniques - Newser
How to build a custom watchlist for Nektar TherapeuticsRate Hike & Weekly Watchlist of Top Performers - Newser
Multi asset correlation models including Nektar TherapeuticsMarket Performance Recap & Advanced Technical Signal Analysis - Newser
What MACD signals say about Nektar Therapeutics2025 Top Decliners & AI Forecasted Entry and Exit Points - Newser
Is Nektar Therapeutics stock ready for a breakoutGap Up & Community Consensus Trade Alerts - Newser
Using data models to predict Nektar Therapeutics stock movement2025 Big Picture & Real-Time Stock Entry Alerts - Newser
Why Nektar Therapeutics stock attracts strong analyst attention2025 Buyback Activity & Fast Gain Stock Trading Tips - Newser
Signal strength of Nektar Therapeutics stock in tech scanners2025 Pullback Review & AI Forecasted Entry/Exit Points - Newser
Using Ichimoku Cloud for Nektar Therapeutics technicals2025 Technical Overview & Smart Investment Allocation Insights - Newser
Nektar Therapeutics stock trend outlook and recovery pathQuarterly Earnings Summary & Capital Efficient Trading Techniques - Newser
Sentiment analysis tools applied to Nektar TherapeuticsShort Setup & AI Enhanced Trade Execution Alerts - Newser
Can Nektar Therapeutics rally from current levelsRecession Risk & Verified High Yield Trade Plans - Newser
How to interpret RSI for Nektar Therapeutics stockJuly 2025 EndofMonth & Capital Protection Trading Alerts - Newser
Applying big data sentiment scoring on Nektar TherapeuticsJuly 2025 Final Week & Risk Adjusted Buy and Sell Alerts - Newser
Comparing Nektar Therapeutics in custom built stock radarsRate Hike & Weekly Watchlist of Top Performers - Newser
Nektar Therapeutics stock volume spike explainedJuly 2025 Technicals & Verified Momentum Stock Watchlist - Newser
What indicators show strength in Nektar TherapeuticsJuly 2025 Pullbacks & Weekly High Conviction Trade Ideas - Newser
News impact scoring models applied to Nektar TherapeuticsMarket Risk Analysis & Long-Term Safe Investment Plans - Newser
Tick level data insight on Nektar Therapeutics volatilityForecast Cut & AI Forecast Swing Trade Picks - Newser
Measuring Nektar Therapeutics’s beta against major indices2025 Year in Review & Reliable Entry Point Trade Alerts - Newser
Can Nektar Therapeutics expand into new markets getLinesFromResByArray error: size == 0 - thegnnews.com
Nektar Therapeutics stock outlook for YEARPortfolio Return Summary & Verified Momentum Stock Ideas - Newser
How to use a screener to detect Nektar Therapeutics breakouts2025 Key Lessons & Weekly Top Stock Performers List - Newser
Certain Stock Options of Nektar Therapeutics are subject to a Lock-Up Agreement Ending on 30-AUG-2025. - MarketScreener
Certain Restricted Stock Units of Nektar Therapeutics are subject to a Lock-Up Agreement Ending on 30-AUG-2025. - MarketScreener
Will Nektar Therapeutics benefit from macro trendsMarket Growth Report & Reliable Price Breakout Alerts - Newser
넥타테라퓨틱스 (NKTR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.96%
1.09%
자본화:
|
볼륨(24시간):